Skip to Main Content


Angiogenesis, Exudation, and Degeneration 2019

Saturday, February 9, 2019
Program is subject to change

7:00 am Registration and Continental Breakfast
7:50 Welcome and Overview / Pre-Program Test
Philip J. Rosenfeld, MD, PhD, Harry W. Flynn, Jr., MD, and Thomas A. Albini, MD
  Session I: Age-Related Macular Degeneration
Moderators: Philip J. Rosenfeld, MD, PhD and Zohar Yehoshua, MD, MHA
8:00 Bioenergetics, Metabolism and Macular Degeneration
Philip Luthert, MBBS

8:10 New Data on the Prevalence of AMD
Professor Jean-FrancoisKorobelnik
8:20 10 Year Follow-up of AREDS2 and More
Emily Y. Chew, MD
8:30 Natural History of Geographic Atrophy Secondary to Age-Related Macular Degeneration: Proxima A and B Clinical Trial Results
Nancy M. Holekamp, MD
8:40 Can Genetics Help Identify Individuals With Intermediate AMD at High Risk of Progression?
Johanna M. Seddon, MD, ScM

8:50 Common Age-related Macular Degeneration Genetic Risk Variants and Geographic Atrophy Lesion Growth in the Phase 3 Lampalizumab Trials: Update
Karl G. Csaky, MD, PhD

9:00 Addressing the Cuticular Drusen Epidemic
Lawrence A. Yannuzzi, MD

9:10 Structural/Dynamic/Functional (OCT/OCTA/MP) Assessment of the Macula
Brandon Lujan, MD

9:20 Ultrahigh Speed and Ultrahigh Resolution OCT for Investigating the Outer Retina and Choriocapillaris
James G. Fujimoto, PhD

9:30 Quantitative Assessment of the Choroidal Vasculature Using Swept Source OCTA
Ruikang Wang, PhD

9:40 OCTA of the Choriocapillaris in AMD
Nadia K.Waheed, MD

9:50 SS-OCTA Imaging of Choriocapillaris Flow Deficits in Non-Exudative AMD and Their Correlation with Disease Progression
Philip J. Rosenfeld, MD, PhD

  Session II: Non-Exudative AMD
Moderators: Thomas A. Albini, MD and Lawrence J. Singerman, MD, FACS
10:00 Retina Trends – A VC’s Perspective
Emmett T. Cunningham, Jr., MD, PhD, MPH

10:10 OCT Risk Factors for Development of Late AMD: A Fellow Eye Analysis from the HARBOR Trial
SriniVas Sadda, MD

10:20 Nanosecond Laser Intervention to Slow AMD Progression
Robyn Guymer, MBBS, PhD, FRANZCO

10:30 Soft Drusen Precursors Removed by a Clinical-Stage Apolipoprotein Mimetic Peptide in A Non-human Primate AMD Model
Christine A. Curcio, PhD, FARVO

10:40 Kamuvudines for Macular Degeneration
Jayakrishna Ambati, MD

10:50 Update on Gene Therapy for Complement Inhibition: 1 Year Results of A Phase 1 Study
Jay S. Duker, MD

11:00 Update for the ReCLAIM Trial: Elamipretide for the Treatment of Vision Loss in Drusen and Noncentral GA
Scott W. Cousins, MD

11:10 TOGA-- Baseline Characteristics and Preliminary Safety Data
Elias Reichel, MD

11:20 Stem Cell Derived RPE Transplantation Surgery for Geographic Atrophy
Amir H. Kashani, MD, PhD

11:30 C3 inhibition in Geographic Atrophy
Cedric G. Francois, MD, PhD

  Session III: High Risk Non-Exudative AMD
Moderators: Harry W. Flynn, Jr., MD and Jaclyn L. Kovach, MD
11:40 The Spectrum of Treatment-Naive Subclinical Macular Neovascularization
Giuseppe Querques, MD, PhD

11:50 Two-Year SS-OCTA Incidence and Natural History of Subclinical Neovascularization in Age-Related Macular Degeneration
Philip J. Rosenfeld, MD, PhD

12:00 pm Pearls from PROCON: What Have We Learned in Year 1 of this 2 Year Trial
Jeffrey S. Heier, MD

12:10 Clear Study of Mobile App to Monitor Visual Function in DR and AMD
Lawrence J. Singerman, MD, FACS

12:20 The Future of AMD Management will Include Home OCT Monitoring by Our Patients
Anat Loewenstein, MD, MHA

12:30 Prevention of Exudative CNV in Eyes with High Risk AMD: Theoretical and Practical Challenges in Clinical Trial Design
Daniel F. Martin, MD

12:40 Lunch
  Session IV: Macular Neovascularization: Imaging and Emerging Therapies
Moderators: Philip J. Rosenfeld, MD, PhD and Ninel Z. Gregori, MD
1:20 Vascular Maturity of Choroidal Neovascularization Evaluated by OCTA
Hiroko Terasaki, MD, PhD

1:30 Polyps in Polypoidal Choroidal Vasculopathy Appear as Tangled Vascular Structures Using Swept-Source OCT Angiography
Fenghua Wang, PhD

1:40 Variations of Choroidal Thickness in CNV
Bruno Lumbroso, MD

1:50 Choroidal Neovascularization: Jekyll or Hyde?
Jason S. Slakter, MD

2:00 Can Exudative AMD Treat Itself?
K. Bailey Freund, MD

2:10 What We Have Learned About Integrins and Their Mechanism of Action
David S. Boyer, MD

2:20 Pan-VEGF Blockade for AMD
Peter K. Kaiser, MD

2:30 KSI-301: Update on Phase 1 Studies with a First in Class Antibody-Biopolymer Conjugate for Treatment of Wet AMD, DME, and Other Retinal Vascular Diseases
Diana V. Do, MD

2:40 Sustained Release Ranibizumab Therapy: The Phase 2 LADDER Study
Carl D. Regillo, MD, FACS

2:50 Phase 1 Results of GB-102: A Novel Bioabsorbable Sustained-release IVT Depot Formulation of Sunitinib for nAMD (ADAGIO Study)
David S. Boyer, MD

3:00 Subretinal Injection of AAV8 Expressing an Anti-VEGF Protein in Patients with Neovascular AMD
Peter A. Campochiaro, MD

3:10 Gene Therapy for Neovascular AMD : Intravitreal Delivery of AAV-7m8 vectors.
David M. Brown, MD

  Session V: Macular Neovascularization, Diabetes, and Anti-VEGF Therapy
Moderators: Harry W. Flynn, Jr. MD and Justin H. Townsend, MD
3:20 Advances in the Development of an Assisted Intravitreal Injection System
Stephan Michels, MD

3:30 Brolucizumab versus Aflibercept for Neovascular AMD: 96-week Expanded Anatomical Outcomes from HAWK and HARRIER"
Pravin U. Dugel, MD

3:40 The Social Cost of Blindness Due to AMD and Diabetes
Andrew A. Moshfeghi, MD, MBA

3:50 Retinal Neurodegeneration and Microangiopathy as Mechanisms of Early DR
Yu Seung-Young, MD

4:00 Relation Between Peripheral and Central Retinal Capillary Non Perfusion is Non Linear in Diabetic Microvascular Disease
Usha Chakravarthy, MD

4:10 Widefield OCT-A in Diabetic Retinopathy
Harry W. Flynn, Jr., MD

4:20 Higher Order Assessment of Optical Coherence Tomography for Quantitative Retinal Features in the VISTA DME Study
Justis P. Ehlers, MD

4:30 Intravitreal Aflibercept for Moderately Severe to Severe Non-Proliferative Diabetic Retinopathy (NPDR): 1-Year Outcomes of the Phase 3 PANORAMA Study
Charles C. Wykoff, MD

4:40 Comparison of wide-field OCTA and Ultrawide-field FA Assessment of Capillary Perfusion in Diabetic Retinopathy After Anti-VEGF Therapy
Ramin Tadayoni, MD, PhD

4:50 Preclinical and Emerging Clinical Evidence Supporting the Rationale for Targeting Angiopoietin2 in Diabetic Eye Disease
Peter A. Campochiaro, MD

5:00 Manipulating the Tie2 Pathway in Diabetic Retinopathy
Peter K. Kaiser, MD

  Session VI: Retinal Vascular Diseases, Uveitis, and Retinal Degenerations
Moderators: Philip J. Rosenfeld, MD, PhD and Janet L. Davis, MD
5:10 Inflammation in Retinal Vascular Diseases: The Role of Interleukin-6 in Age-Related Macular Degeneration and Diabetic Macular Edema
Quan Dong Nguyen, MD

5:20 The Long-Term Physical Stability, Sterility and Anti-VEGF Bio-Activity of Repackaged Bevacizumab in 2 mL Glass Vials: Findings from SCORE2
Michael S. Ip, MD

5:30 Anti-VEGF Therapy in ROP
Darius M. Moshfeghi, MD

5:40 ZIPANGU: A Comparison Study of Anti-VEGF Therapy with or Without OCTA Guided Focal/Grid Laser for Macular Edema Secondary to BRVO
Toshinori Murata, MD, PhD

5:50 Macular Pigment: An Important Technique to Detect Mueller’s Cells Diseases
Giovanni Straurenghi, MD

6:00 Is MacTel a “Serine-Opathy?
Martin Friedlander, MD, PhD

6:10 A Deep Learning Approach to Quantify Ellipsoid Zone Loss in MacTel2 and Other Macular Diseases
Glenn J. Jaffe, MD

6:20 Suprachoroidal Delivery of Steroids in Uveitis
Thomas A. Albini, MD

6:30 EYS606 - Non Viral Gene Therapy for the Treatment of Non Infectious Uveitis
Sunil K. Srivastava, MD

6:40 Treatments and Clinical Trials in Inherited Retinal Degenerations
Byron L. Lam, MD

6:50 Clinical Trials in Stargardt Disease
Carel B. Hoyng, MD

7:00 Post-Program Test and Closing Remarks
7:05 Adjourn/Cocktail Reception